1056675-39-8

Usage

Uses

Used in Organic Synthesis:
(1R,S)-1-(tert-butoxycarbonylamino)-1-(3-(hydroxymethyl)pheny)ethane is used as a building block for the production of various pharmaceuticals and agrochemicals. Its chiral nature allows for the creation of enantiomerically pure compounds, which are essential for the development of effective and safe drugs.
Used in Research and Development:
(1R,S)-1-(tert-butoxycarbonylamino)-1-(3-(hydroxymethyl)pheny)ethane is used as a reagent in the preparation of other complex organic molecules and is also used in the study of organic chemistry and drug development. Its precise structure allows for specific interactions with biological targets, making it an important tool for the development of new drugs and treatments.
Used in Pharmaceutical Industry:
(1R,S)-1-(tert-butoxycarbonylamino)-1-(3-(hydroxymethyl)pheny)ethane is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique properties enable the development of innovative drugs with improved efficacy and selectivity.
Used in Agrochemical Industry:
(1R,S)-1-(tert-butoxycarbonylamino)-1-(3-(hydroxymethyl)pheny)ethane is used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its versatility in organic synthesis allows for the creation of novel compounds with enhanced performance and reduced environmental impact.

Upstream product

• 1056675-31-0 (1R,S)-1-(t-butoxycarbonylamino)-1-(3-(4-methoxytrityloxymethyl)phenyl) ethane 
• 165949-84-8 3-<1'-<(tert-butyloxycarbonyl)amino>ethyl>benzoic acid 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 1187930-71-7 3-(1-amino-ethyl)-benzoic acid 
• 1056675-27-4 3-(4-methoxytrityloxymethyl)benzonitrile 
• 1056675-35-4 C₂₉H₂₉NO₂ 
• 874-97-5 3-(hydroxymethyl)benzonitrile 

Downstream Products

• 1056675-43-4 (1R,S)-1-(3-(bromomethyl)phenyl)-1-(t-butoxycarbonylamino)ethane 
• 1349734-59-3 tert-butyl 1-(3-(chloro(hydroxyimino)methyl)phenyl)ethylcarbamate 
• 1349734-55-9 tert-butyl N-[1-[3-(hydroxymethyl)phenyl]ethyl]carbamate 
• 1349734-57-1 tert-butyl 1-(3-((hydroxyimino)methyl)phenyl)ethylcarbamate 
• 1349732-14-4 5-(5-amino-6-(3-(3-(1-aminoethyl)phenyl)isoxazol-5-yl)pyrazin-2-yl)-1-(1-cyclopropylethyl)pyridin-2(1H)-one 
• 1349734-73-1 tert-butyl N-tert-butoxycarbonyl-N-[3-[3-[3-[1-(tert-butoxycarbonylamino)ethyl]phenyl]isoxazol-5-yl]-5-[1-(1-cyclopropylethyl)-6-oxo-3-pyridyl]pyrazin-2-yl]carbamate 
• 1056675-47-8 2,3-dideoxy-6-O-(3-(((1R,S)-1-tert-butoxycarbonylamino)ethyl)benzyl)-2-isopropyl-D-glucono-1,4-lactone 
• 1056675-55-8 (2S,4S,5S)-5-azido-6-(3-((1RS)-1-(t-butoxycarbonylamino)ethyl)benzyloxy)-4-hydroxy-2-isopropyl-hexanoic acid ((S)-1-benzylcarbamoyl-2-methyl-propyl)-amide 
• 1079398-50-7 N-{4R-(1S-benzylcarbamoyl-2-methylpropylcarbamoyl)-1S-[3-(1R/S-tert-butoxycarbonyl-aminoethyl)-benzyloxymethyl]-2S-hydroxy-4R-methoxybutyl}-5-(methanesulphonylmethylamino)isophthalamic acid tert-butyl ester 
• 1079398-47-2 (1R/S-{3-[2S-amino-5R-(1S-benzylcarbamoyl-2-methylpropylcarbamoyl)-3S-hydroxy-5R-methoxypentyloxymethyl]-phenyl}-ethyl) carbamic acid tert-butyl ester 
• 1079398-45-0 (1R/S-{3-[2R-hydroxy-2R-(4R-methoxy-5-oxotetrahydrofuran-2S-yl)ethoxymethy]-phenyl}-ethyl)carbamic acid-tert-butylester 
• 1079398-46-1 (1R/S-{3-[2S-azido-2S-(4R-methoxy-5-oxotetrahvdrofuran-2S-yl)ethoxymethyl]-phenyl} - ethyl)-carbamic acid-tert-butylester 
• 1353571-19-3 1-[3-[5-[2-(4-isopropylsulfonylphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]isoxazol-3-yl]phenyl]ethanamine 
• 1353571-96-6 tert-butyl N-[1-[3-[5-[2-(4-isopropylsulfonylphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]isoxazol-3-yl]phenyl]ethyl]carbamate 

Relevant academic research and scientific papers

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I wherein the variables are as defined herein.

PYRROLO- PYRAZINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE

The present invention relates to pyrrolopyrazines compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various disea

Design and synthesis of potent macrocyclic renin inhibitors

Two types of P1-P3-linked macrocyclic renin inhibitors containing the hydroxyethylene isostere (HE) scaffold just outside the macrocyclic ring have been synthesized. An aromatic or aliphatic substituent (P3sp) was introduced in the macrocyclic ring aiming

ASPARTYL PROTEASE INHIBITORS

The invention provides compounds of the formula (I) wherein A is selected from the partial structures A1, A2 and A3; Ry and Ry' are both hydrogen, or Ry and Ry' together with the nitrogen atom to which they are attached form a cyclic amine such as morpholine, piperidine, piperazine or pyrrolidine; L is NHNH, CH2NH, O or S; Y is NH, NHNH, NHC(=O), S(=O)2NH, NHS(=O)2, CH2, CH2NH, O, S or S(=0)p; Q is aryl or heterocyclyl; Z is O, S, NRa or S(=0)p; m is O, 1 or 2; n is O, 1, 2 or 3; p is independently 1 or 2; q is 0 or 1; Ra is H or C1-C4alkyl; R1 is hydrogen, C1-C6alkyl, C3-C7cycloalkylC0-C3alkyl, arylC0-C3alkyl or heterocyclylC0-C3alkyl, R4'' is H or C1-C6alkyl; or R4' and R4'' together with the carbon atom to which they are attached define a C3-C6cycloalkyl; W is H, C1-C6alkyl, C3-C7ycycloalkyl, aryl or heterocyclyl; or a pharmaceutically acceptable salt, hydrate or N-oxide thereof. The compounds of the invention are inhibitors of aspartyl proteases such as renin and are among other things useful for the treatment of conditions associated with activities of the RAS, such as hypertension, heart failure and renal insufficiency.

NEW COMPOUNDS

The invention provides compounds of the formula I wherein Q is aryl or heterocyclyl any of which is optionally substituted; Z is O, S, NRa or S(=O)p; Y is NH, NHNH, CH2NH, O, S or S(=O)p; n is 0, 1, 2 or 3; m is 0, 1 or 2; p is 1 or 2; Ra is H or C1-C4alkyl; R1 is hydrogen, C1-C6alkyl, C0-C3alkanediylC3-C7cycloalkyl, C0-C3alkanediylaryl or C0- C3alkanediylheterocyclyl; R2 is hydrogen or C1-C6alkyl; X' is hydrogen, fluoro, hydroxy, amino or C1-C6alkoxy; X" is hydrogen, or when X' is fluoro, then X" may also be fluoro; R3is C1-C6alkyl; R4' is C1-C6alkyl; R4" is H or C1-C6alkyl; or R4' and R4" together with the carbon atom to which they are attached define a C3-C6cycloalkyl; W is C1-C6alkyl, C3-C7cycloalkyl, aryl or heterocyclyl any of which is optionally substituted; or a pharmaceutically acceptable salt, hydrate or N-oxide thereof. The compounds of the invention are inhibitors of aspartyl proteases such as renin and are among other things useful for the treatment of conditions associated with activities of the RAS, such as hypertension, heart failure and renal insufficiency.

ASPARTYL PROTEASE INHIBITORS

The invention provides compounds of the formula (I) N-oxides, addition salts, quaternary amines, metal complexes, stereochemically isomeric forms and metabolites thereof, wherein G is-O-, -S(=O)r-, -CRdRd or -NRa-; W is H, C1-C6